MOTS-c and Creatine: Two Evidence Streams, No Combination Study

“No Interaction Found” Is Not the Same as “Studied Together”

A database may contain no listed interaction because no direct study exists. That absence cannot establish that two products are compatible, require dose separation, or are safe for a particular person.

The evidence is asymmetric. Creatine monohydrate has a large human literature. MOTS-c does not have an administered-human record in FDA’s July 2026 evaluation. A responsible answer must keep those streams separate.

The Two-Stream Interaction Matrix

The combination column is empty. That is the core finding.

What the Best Current Creatine Synthesis Says

A 2026 systematic review and meta-analysis included 19 randomized controlled trials and one randomized crossover study. Creatine was associated with a mean serum-creatinine increase of 0.13 mg/dL; pooled urea and eGFR differences were not statistically significant. The authors concluded:

“Cre supplementation seems to relate to an increase in serum Crn, but this is not related to significant alterations in urea concentrations and eGFR.”

Andreas Tsiaras and colleagues are medical and nutrition researchers affiliated with Aristotle University of Thessaloniki and collaborating institutions. This 24-word conclusion applies to the included creatine studies. It does not establish kidney safety for every dose, duration, condition, product, or MOTS-c combination and does not imply endorsement (PMID 42035842; DOI 10.1053/j.jrn.2026.04.010).

A separate 2025 systematic review similarly found a modest, likely transient increase in serum creatinine without a significant GFR change, while emphasizing study heterogeneity and the value of longer-term data (PMID 41199218; PMCID PMC12590749).

Why a Creatinine Change Can Matter Clinically

Creatinine-based eGFR equations use serum creatinine as an input. If creatine supplementation changes serum creatinine without the same change in filtration, the calculated eGFR may move. That is an interpretation issue, not proof of injury and not proof that injury is impossible.

Clinical context still matters: baseline kidney function, trend, hydration, muscle mass, dose, duration, other supplements and medicines, symptoms, and the reason testing was ordered. Alternative filtration markers may be useful in some circumstances, but the evidence cited here does not create a universal cystatin-C testing interval or a percentage threshold for stopping this unstudied combination.

The MOTS-c Side of the Matrix Is the Limiting Factor

FDA’s Center for Drug Evaluation and Research reported in July 2026 that it had not identified human exposure data for MOTS-c by any route. The review also found no human pharmacokinetic study and discussed potential injectable-product concerns involving aggregation, peptide-related impurities, and immunogenicity (FDA briefing, sections II.C.2 and II.D.2, PDF pages 15–16 and 27–29).

Those findings invalidate confident claims that MOTS-c and creatine use different proven human clearance pathways or lack a pharmacokinetic interaction. MOTS-c cell and mouse mechanisms do not supply the missing human absorption, distribution, metabolism, excretion, or combination data.

The rare-but-serious risk review separates those potential product risks from adverse events actually observed in people.

AMPK Does Not Settle Compatibility

The founding MOTS-c paper reported metabolic effects involving the folate cycle and AMPK in cells and mice (PMID 25738459; DOI 10.1016/j.cmet.2015.02.009). Creatine supports phosphocreatine energy buffering and has its own exercise-signaling literature.

From those separate mechanisms, marketers sometimes conclude that creatine and MOTS-c are complementary; others claim creatine’s energy buffering will blunt MOTS-c signaling. Neither conclusion has been tested in an administered-human combination study. A pathway diagram cannot predict the net clinical effect of two exposures across tissues and time.

The exercise evidence audit shows the same transfer problem when endogenous human MOTS-c responses are presented as proof of an injected “exercise mimetic.”

What the Recruiting Trial May—and May Not—Add

NCT07505745 is recruiting adults with prediabetes and overweight or obesity for a randomized MOTS-c-versus-placebo study. It lists insulin sensitivity, adverse events, glucose outcomes, and antidrug antibodies, but no results are posted. The registry does not identify a creatine-combination arm (ClinicalTrials.gov, NCT07505745).

Future results could add information about the study product and selected participants. They would not directly validate a creatine combination that the trial did not test.

A Product-and-Lab Timeline Is More Useful Than a Stack Rule

If someone already uses both products, the useful record is factual:

1. When creatine began, the exact product, daily amount, and any loading phase.
2. When the product labeled MOTS-c began, its source, lot, concentration, route, and directions.
3. Kidney-marker results before and after each change, including which eGFR equation or marker was used.
4. Hydration, illness, exercise, diet, muscle-mass change, and medicines around each test.
5. Symptoms and the dates they appeared or resolved.

This timeline lets a clinician interpret a change without assuming causation. It does not make continued exposure safe or turn the page into a dosing protocol.

The young-adult evidence map explains why age-specific monitoring cannot be manufactured from observational data.

Medical review of this revision is pending. FDA, investigators, authors, journals, institutions, and quoted authorities do not endorse MOTS-c, creatine products, HealthRX.com, or this page.